- Home
- ZM vs RPRX Comparison
ZM vs RPRX Comparison
Compare ZM & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZM | RPRX |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8B | 19.5B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZM | RPRX |
|---|---|---|
| Price | $86.89 | $48.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 4 |
| Target Price | ★ $94.14 | $50.00 |
| AVG Volume (30 Days) | ★ 3.6M | 2.7M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.93% |
| EPS Growth | ★ 92.52 | N/A |
| EPS | ★ 6.18 | 1.78 |
| Revenue | ★ $4,868,769,000.00 | $2,378,193,000.00 |
| Revenue This Year | $7.30 | $38.30 |
| Revenue Next Year | $3.96 | $4.80 |
| P/E Ratio | ★ $14.40 | $27.33 |
| Revenue Growth | 4.36 | ★ 5.06 |
| 52 Week Low | $69.15 | $31.58 |
| 52 Week High | $97.58 | $49.06 |
Technical Indicators
Market Signals| Indicator | ZM | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 59.34 |
| Support Level | $86.74 | $35.32 |
| Resistance Level | $91.12 | $49.06 |
| Average True Range (ATR) | 3.35 | 0.90 |
| MACD | 0.90 | 0.04 |
| Stochastic Oscillator | 72.19 | 75.33 |
Price Performance
Historical ComparisonAbout ZM Zoom Video Communications Inc.
Zoom Communications provides a video-first communications platform that connects people through frictionless video, voice, chat, and content sharing. The company's cloud-native platform enables video experiences and connects users across various devices and locations in a single meeting. Zoom has launched a variety of communications-related solutions, including Zoom Phone and Zoom Contact Center. The firm was founded in 2011 and serves companies of all sizes from all industries around the world.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.